The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://joyceyyck307464.tusblogos.com/39513186/glp-3-retatrutide-a-comparative-analysis